Cargando…

Inhibition of Angiopoietin-2 Production by Myofibrocytes Inhibits Neointimal Hyperplasia After Endoluminal Injury in Mice

Fibrocytes are myeloid lineage cells implicated in wound healing, repair, and fibrosis. We previously showed that fibrocytes are mobilized into the circulation after vascular injury, including the immune-mediated injury that occurs after allogeneic transplantation. A common response to inflammatory...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Daxin, Li, Ke, Tham, El-Li, Wei, Lin-Lin, Ma, Ning, Dodd, Philippa C., Luo, Yi, Kirchhofer, Daniel, McVey, John H., Dorling, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036182/
https://www.ncbi.nlm.nih.gov/pubmed/30013567
http://dx.doi.org/10.3389/fimmu.2018.01517
_version_ 1783338122533142528
author Chen, Daxin
Li, Ke
Tham, El-Li
Wei, Lin-Lin
Ma, Ning
Dodd, Philippa C.
Luo, Yi
Kirchhofer, Daniel
McVey, John H.
Dorling, Anthony
author_facet Chen, Daxin
Li, Ke
Tham, El-Li
Wei, Lin-Lin
Ma, Ning
Dodd, Philippa C.
Luo, Yi
Kirchhofer, Daniel
McVey, John H.
Dorling, Anthony
author_sort Chen, Daxin
collection PubMed
description Fibrocytes are myeloid lineage cells implicated in wound healing, repair, and fibrosis. We previously showed that fibrocytes are mobilized into the circulation after vascular injury, including the immune-mediated injury that occurs after allogeneic transplantation. A common response to inflammatory vascular injury is intimal hyperplasia (IH), which, alongside vascular remodeling, results in progressive loss of blood flow, downstream ischemia, and end-organ fibrosis. This forms the pathological basis of transplant arteriosclerosis and other diseases including post-angioplasty re-stenosis. In investigating whether fibrocytes contribute to IH, we previously showed that subpopulations expressing smooth muscle actin and CD31 are recruited to the site of injury and accumulate in the neointima. Expression of tissue factor (TF) by these “CD31+ myofibrocytes” is needed for progressive neointimal expansion, such that TF inhibition limits the neointima to a single layer of cells by day 28 post-injury. The aim of this study was to determine pathophysiological mediators downstream of TF that contribute to myofibrocyte-orchestrated IH. We first show that myofibrocytes make up a significant component of the neointima 28 days following injury. Using a previously defined adoptive transfer model, we then show that CD31+ myofibrocytes get recruited early to the site of injury; this model allows manipulations of the adoptively transferred cells to study how IH develops. Having confirmed that inhibition of TF on adoptively transferred cells prevents IH, we then show that TF, primarily through the generation of thrombin, induces secretion of angiopoietin-2 by myofibrocytes and this directly stimulates proliferation, inhibits apoptosis, and induces CXCL-12 production by neointimal cells, including non-fibrocytes, all of which promote progressive IH in vivo. Prior incubation to inhibit angiopoietin-2 secretion by or block TIE-2 signaling on adoptively transferred fibrocytes inhibits IH. These novel data indicate that angiopoietin-2 production by early recruited myofibrocytes critically influences the development of IH after vascular injury and suggest new therapeutic avenues for exploration.
format Online
Article
Text
id pubmed-6036182
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-60361822018-07-16 Inhibition of Angiopoietin-2 Production by Myofibrocytes Inhibits Neointimal Hyperplasia After Endoluminal Injury in Mice Chen, Daxin Li, Ke Tham, El-Li Wei, Lin-Lin Ma, Ning Dodd, Philippa C. Luo, Yi Kirchhofer, Daniel McVey, John H. Dorling, Anthony Front Immunol Immunology Fibrocytes are myeloid lineage cells implicated in wound healing, repair, and fibrosis. We previously showed that fibrocytes are mobilized into the circulation after vascular injury, including the immune-mediated injury that occurs after allogeneic transplantation. A common response to inflammatory vascular injury is intimal hyperplasia (IH), which, alongside vascular remodeling, results in progressive loss of blood flow, downstream ischemia, and end-organ fibrosis. This forms the pathological basis of transplant arteriosclerosis and other diseases including post-angioplasty re-stenosis. In investigating whether fibrocytes contribute to IH, we previously showed that subpopulations expressing smooth muscle actin and CD31 are recruited to the site of injury and accumulate in the neointima. Expression of tissue factor (TF) by these “CD31+ myofibrocytes” is needed for progressive neointimal expansion, such that TF inhibition limits the neointima to a single layer of cells by day 28 post-injury. The aim of this study was to determine pathophysiological mediators downstream of TF that contribute to myofibrocyte-orchestrated IH. We first show that myofibrocytes make up a significant component of the neointima 28 days following injury. Using a previously defined adoptive transfer model, we then show that CD31+ myofibrocytes get recruited early to the site of injury; this model allows manipulations of the adoptively transferred cells to study how IH develops. Having confirmed that inhibition of TF on adoptively transferred cells prevents IH, we then show that TF, primarily through the generation of thrombin, induces secretion of angiopoietin-2 by myofibrocytes and this directly stimulates proliferation, inhibits apoptosis, and induces CXCL-12 production by neointimal cells, including non-fibrocytes, all of which promote progressive IH in vivo. Prior incubation to inhibit angiopoietin-2 secretion by or block TIE-2 signaling on adoptively transferred fibrocytes inhibits IH. These novel data indicate that angiopoietin-2 production by early recruited myofibrocytes critically influences the development of IH after vascular injury and suggest new therapeutic avenues for exploration. Frontiers Media S.A. 2018-07-02 /pmc/articles/PMC6036182/ /pubmed/30013567 http://dx.doi.org/10.3389/fimmu.2018.01517 Text en Copyright © 2018 Chen, Li, Tham, Wei, Ma, Dodd, Luo, Kirchhofer, McVey and Dorling. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Chen, Daxin
Li, Ke
Tham, El-Li
Wei, Lin-Lin
Ma, Ning
Dodd, Philippa C.
Luo, Yi
Kirchhofer, Daniel
McVey, John H.
Dorling, Anthony
Inhibition of Angiopoietin-2 Production by Myofibrocytes Inhibits Neointimal Hyperplasia After Endoluminal Injury in Mice
title Inhibition of Angiopoietin-2 Production by Myofibrocytes Inhibits Neointimal Hyperplasia After Endoluminal Injury in Mice
title_full Inhibition of Angiopoietin-2 Production by Myofibrocytes Inhibits Neointimal Hyperplasia After Endoluminal Injury in Mice
title_fullStr Inhibition of Angiopoietin-2 Production by Myofibrocytes Inhibits Neointimal Hyperplasia After Endoluminal Injury in Mice
title_full_unstemmed Inhibition of Angiopoietin-2 Production by Myofibrocytes Inhibits Neointimal Hyperplasia After Endoluminal Injury in Mice
title_short Inhibition of Angiopoietin-2 Production by Myofibrocytes Inhibits Neointimal Hyperplasia After Endoluminal Injury in Mice
title_sort inhibition of angiopoietin-2 production by myofibrocytes inhibits neointimal hyperplasia after endoluminal injury in mice
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036182/
https://www.ncbi.nlm.nih.gov/pubmed/30013567
http://dx.doi.org/10.3389/fimmu.2018.01517
work_keys_str_mv AT chendaxin inhibitionofangiopoietin2productionbymyofibrocytesinhibitsneointimalhyperplasiaafterendoluminalinjuryinmice
AT like inhibitionofangiopoietin2productionbymyofibrocytesinhibitsneointimalhyperplasiaafterendoluminalinjuryinmice
AT thamelli inhibitionofangiopoietin2productionbymyofibrocytesinhibitsneointimalhyperplasiaafterendoluminalinjuryinmice
AT weilinlin inhibitionofangiopoietin2productionbymyofibrocytesinhibitsneointimalhyperplasiaafterendoluminalinjuryinmice
AT maning inhibitionofangiopoietin2productionbymyofibrocytesinhibitsneointimalhyperplasiaafterendoluminalinjuryinmice
AT doddphilippac inhibitionofangiopoietin2productionbymyofibrocytesinhibitsneointimalhyperplasiaafterendoluminalinjuryinmice
AT luoyi inhibitionofangiopoietin2productionbymyofibrocytesinhibitsneointimalhyperplasiaafterendoluminalinjuryinmice
AT kirchhoferdaniel inhibitionofangiopoietin2productionbymyofibrocytesinhibitsneointimalhyperplasiaafterendoluminalinjuryinmice
AT mcveyjohnh inhibitionofangiopoietin2productionbymyofibrocytesinhibitsneointimalhyperplasiaafterendoluminalinjuryinmice
AT dorlinganthony inhibitionofangiopoietin2productionbymyofibrocytesinhibitsneointimalhyperplasiaafterendoluminalinjuryinmice